Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis

计划入组 20 人 · 首次发布于 2024 年 10 月 31 日

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

计划入组 70 人 · 首次发布于 2025 年 1 月 14 日

HERO-UTUC: Intravesical RC48 After RNU for HER2+ UTUC

计划入组 49 人 · 首次发布于 2026 年 5 月 18 日

LG-2293

LG-121071

LG-120747

LG Chem, Ltd.

South Korea

LG Chem Ltd.

South Korea

LG Household & Health Care Ltd.

South Korea

JELMYTO Demonstrates Durable Response in Low-Grade Upper Tract Urothelial Cancer

UroGen Pharma's UGN-102 Shows Promise in Bladder Cancer Treatment

ImPact Biotech to Present Phase 3 Data on Padeliporfin for Low-Grade UTUC at EMUC 2024